We performed a randomized comparison of pre-emptive and empiric antibiotic therapy for adult patients undergoing allogeneic or autologous stem cell transplantation. One hundred and fifty-three patients were randomized to receive cefepime either pre-emptively on the day that neutropenia (ANCo1.0 Â 10 9 cells/l) developed irrespective of the presence of fever, or at onset of fever and neutropenia (empiric). Although there was no difference between the two arms in the proportion of patients developing fever or in the median number of days of fever, the time to onset of fever was a mean of 1 day longer in each patient on the pre-emptive arm (log rank Po0.001). The number of patients with bloodstream infections was significantly reduced in those receiving pre-emptive therapy (16/75) compared to the empiric arm (31/76) (Po0.01) but this did not translate into an appreciable clinical benefit as measured by days of hospitalization, time to engraftment, use of additional antimicrobial agents or mortality at 30 days. This study does not support the use of pre-emptive intravenous antibiotic therapy in adult stem cell transplant recipients.
Introduction
Fever occurs in 490% of allogeneic hematopoietic stem cell transplant (HSCT) 1, 2 and 80% of autologous HSCT recipients. 3 Empiric antibacterial regimens such as b-lactam or carbapenem monotherapy or a combination of betalactam and an aminoglycoside are recommended to treat fever in the neutropenic patient. 4 Despite empiric antibacterial therapy, mortality ranging up to 10% is associated with fever and neutropenia, particularly in those with an expected duration of neutropenia (ANC o0.5 Â 109/l) 410 days. 5 Inadequate or delayed therapy of the initial pathogen has been associated with increased mortality 6 as has been the presence of underlying comorbidities. 5 Prophylaxis with oral levofloxacin decreased bloodstream infections (BSIs) in one randomized placebocontrolled study, although patients were exclusively undergoing autologous transplantation, and most were receiving therapy for solid tumours rather than leukaemia or lymphoma. 7 The use of prophylactic oral fluoroquinolones remains controversial [8] [9] [10] [11] and the effects of oral antibiotics used prophylactically may not equate to intravenous agents. 12 We and others have hypothesized that pre-emptive intravenous antibiotic therapy, that is, antibiotics commenced at onset of neutropenia or on day of transplant (also referred to as prophylactic antibiotics in some recent publications), would reduce the incidence of fever and bacterial infection during the acute phase of transplantation. 2, 13, 14 However, pre-emptive intravenous antibiotic therapy has not been well evaluated in HSCT although two non-randomized studies have suggested that patients may benefit from this approach. 13, 14 The present study was designed to compare the occurrence of fever, bacterial infection, antibiotic usage and outcome of adult patients undergoing either allogeneic or autologous stem cell transplant in patients randomized to receive either empiric antibiotic therapy, started at onset of fever, or pre-emptive antibiotic therapy, started at onset of significant neutropenia.
Patients and methods
The study was conducted at two adult bone marrow transplant centres in Melbourne, Australia. All patients admitted for HSCT were approached for consent to participate. Patients previously randomized, receiving systemic antibiotics (except for Pneumocystis jirovecii or post-splenectomy prophylaxis) or with documented betalactam allergy, fever or infection at the time of admission for conditioning for HSCT were excluded. Fluoroquinolone prophylaxis was not used in either centre during the period of this study. Patients were followed prospectively from time of randomization through to discharge. Deaths occurring up to 3 months after transplant were recorded. Maximum temperature, additional antimicrobials prescribed and their doses and all positive microbiology results were recorded daily. Date of engraftment was recorded and time to all events was from date of transplant. The research and ethics committees of both hospitals approved the protocol.
Definitions
For the purpose of starting either empiric or pre-emptive antibiotic treatment, and to account for rapidly declining neutrophil counts with conditioning, neutropenia was defined as ANCo1.0 Â 10 9 /l. Time to engraftment was defined as time from transplant until the neutrophil count exceeded 0.5 Â 10 9 /l. Fever was an oral temperature of 38.31C on one occasion, or two temperatures of X381C separated by at least 1 h, not associated with infusion of blood products. Severe sepsis was defined as fever accompanied by a reduction of systolic blood pressure to o100 mm Hg or a 420 mm Hg decrease from baseline or pulse 4120/min. BSI was any organism detected from at least one blood culture. Where more than one species was isolated on a single blood culture, this was considered as one infection but designated as polymicrobial. When the same organism was isolated on a sample taken within 14 days of the first positive culture, this was counted as one infection. Standard microbiological methods were used for culture and identification of bacteria and fungi.
Antimicrobial protocols
Pre-emptive therapy with cefepime began on the first day after randomization when the ANC was o1.0 Â 10 9 /l and decreasing. The empiric therapy with cefepime began when a patient with a neutrophil count o1.0 Â 10 9 /l developed a fever. The dose of cefepime was 1 g intravenously 12 hourly, which was increased to 2 g 12 hourly for severe sepsis as defined above. The addition of gentamicin, metronidazole and vancomycin was recommended for severe sepsis. The use of vancomycin was also permitted for evidence of central line infection, and metronidazole for diarrhoea or clinical suspicion of neutropenic enterocolitis defined by unexpected or severe nausea, vomiting, diarrhoea, abdominal pain or ileus. The addition of empiric antifungal therapy (amphotericin B at 0.5-1 mg/kg/day) was considered during neutropenia at or after 5 days of persistent fever despite antibiotics, or upon development of new fever after 48 h without fever. If an infection was identified, treatment was modified appropriately according to antibiotic susceptibility that was performed by disc diffusion according to the Clinical and Laboratory Standards Institute guidelines. 15 Details of all antimicrobials given after transplantation were recorded.
Antifungal and antiviral prophylaxis and treatment All patients were in-patients in high efficiency particulate air-filtered rooms from the start of conditioning to engraftment. The use of prophylactic antifungal, antiviral and growth factor therapy was according to the unit protocols. Briefly, for allogeneic HSCT recipients, fluconazole was used as antifungal prophylaxis at a dose of 400 mg/day from the onset of neutropenia to neutrophil recovery. All patients seropositive for herpes simplex virus or varicella zoster virus received acyclovir 400 mg orally twice daily or dose 250 mg intravenously three times daily from onset of neutropenia until hospital discharge.
Severity of sepsis
A further analysis was performed on the occurrence and severity of sepsis syndrome in the cohort of patients treated at Centre 2. Charts were reviewed by an investigator not involved in the initial study (AS). At the time of fever, patients were categorized as to the severity of sepsis according to the following scale: grade 1 uneventful, grade 2 intermediate (one or more of temperature 4391C, rigors, heart rate 4120/min, respiratory rate 420/min, new pulmonary infiltrate on chest radiograph, fluid resuscitation o500 ml/h required), grade 3 severe (one or more of altered mental status, respiratory rate increase from baseline greater than 10/min, systolic blood pressure o90 mm Hg or decrease 440 mm Hg from baseline, pulse oximetry o90% on room air, acidosis (pHo7.36), coagulation abnormalities (INR41.5, APTT460 s), rise in serum creatinine 450% above baseline, rise in bilirubin 470 mmol/l, fluid resuscitation 4500 ml/h required). Admission to intensive care unit (ICU) was also recorded.
Transplantation protocols
Standard prophylaxis for graft-versus-host disease (GVHD) included the use of cyclosporine and short-course methotrexate. 16 Corticosteroids were not used prophylactically. Treatment of moderate to severe GVHD consisted of optimization of cyclosporin levels and commencement of iv methylprednisolone 1-2 mg/kg/day or an equivalent oral prednisolone dose.
Statistical analysis
Randomization was on a 1:1 ratio to receive either preemptive or empiric therapy in blocks of 4 with the study arm randomly allocated within those blocks and concealed before randomization. Stratification was for the centre at which the transplant was performed (centre 1 or centre 2) and stem cell source (allogeneic or autologous). The sample size was calculated at 67 patients per arm based on numbers required to detect a change in the incidence of fever from 95 to 75% in the pre-emptive antibiotic arm at the 0.05 significance level with 80% power. The aim was to enrol 140 patients to account for patient withdrawals and loss to follow-up.
The primary end points were occurrence of fever and days with fever during the transplant admission. Secondary end points were number of bacterial BSIs, total number of systemic antimicrobial agents added (including antiviral and antifungal as well as antibacterial agents), duration of hospitalization for transplant and 30-day mortality. All patients randomized were analysed (intention to treat) unless HSCT did not occur or consent for study was withdrawn. Time was counted from the day of transplant, and expressed as median number of days, with 95% confidence interval (CI). Times to event outcomes were analysed by the Kaplan-Meier method.
The Poisson regression approach was also used to model the data as Poisson data (skewed distribution, non-negative values and increasing variance as the mean increases) and accounting for the varying times 'at risk'. Negative binomial regression uses a log transformation that adjusts for the skewness and prevents the model from producing negative predicted values. It also models the variance as a function of the mean. 17 Exposure was determined as the time (in days) from the date of transplant to the date of discharge or date of death, whichever came earlier. The number of days with fever across this time period could then be determined. Days without data simply did not contribute to the analysis, but did not cause the patients to be censored. For the analysis of days with fever, the following prognostic factors were also included in the model: age, transplant type, time to neutropenia from date of transplant, use of total body irradiation (TBI) in the conditioning regimen and hospital. These terms were included in all models, together with treatment, irrespective of attainment of statistical significance. According to the statistical goodness of fit statistics, an overdispersed Poisson model (negative binomial model) was used for all models except the model for antibiotic exposure, which was underdispersed. Estimates of treatment mean rates were derived from the model, adjusted for age, transplant type, time to neutropenia (from date of transplant) use of TBI and treating hospital.
A Cox proportional hazards model was fitted to model for time to onset of fever including risk factors for fever. Variables included in the model were hospital, transplant type (allogeneic or autologous), use of TBI, age and time to neutropenia.
For comparison of proportions, Fisher's exact test was used. Statistical calculations were performed with the use of STATA software (version 8, Stata Corporation, TX, USA).
Results
One hundred and fifty-three patients were randomized over a 26-month period. After randomization, two patients were excluded from the analysis either owing to failure of the transplant to proceed (n ¼ 1) or because consent for the study was withdrawn before any study drug was administered (n ¼ 1). Of the 151 patients included in the modified intent to treat analysis, 75 received pre-emptive and 76 empiric therapy. Seventy-nine patients (52%) had undergone allogeneic HSCT and of these 58% received TBI as part of the conditioning regimen and 37% received mismatched grafts. Ex vivo T cell depletion was used in only one allograft although in vivo T cell depletion with ATG (antithymocyte globulin) was used in 19 patients as part of the conditioning regimen. Among allogeneic transplant recipients, the stem cell source was peripheral blood in 44 and bone marrow in 35, and both stem cell sources were distributed evenly between antibiotic treatment arms. All except one of the autologous transplant recipients received peripheral blood stem cells. Patient demographics are shown in Table 1 .
Time to fever and duration of fever Despite receiving pre-emptive antibiotics, 66/72 (92%) patients in the pre-emptive arm developed a fever during their in-patient admission, a rate similar to that observed in the empiric arm where 73/75 (97%) patients developed fever and required treatment with antibiotics (P ¼ 0.16) ( Table 2) . Data relating to onset of fever were missing for three additional patients in the pre-emptive and one additional patient in the empiric arm. The median time from transplant to the onset of the first fever was 7 days (95% CI 7,8) in patients receiving pre-emptive antibiotics and 6 days (95% CI 5,6 days) in patients receiving empiric antibiotics, as calculated by Kaplan-Meier survival curve (Po0.001) (Figure 1 ). The Cox proportional hazards model for time to onset of fever showed that the study arm remained significant (Po0.001) with patients on the empiric arm having a hazard ratio of 2.42 (95% CI Table 1 Demographics of 151 patients receiving either pre-emptive or empiric antibiotic therapy in modified intent to treat analysis 1.68-3.49) for developing fever at any given time point from transplant compared to those on the pre-emptive arm. Fever may be caused by noninfective inflammatory processes, particularly post-engraftment in patients undergoing allogeneic transplantation. As pre-emptive antibiotics were hypothesized to reduce fever related to infections during the neutropenic phase of transplantation, we performed a post hoc analysis of the incidence of any fever from day of infusion to day of engraftment. Nine patients receiving pre-emptive antibiotics and five in the empiric arm developed their first fever after engraftment, and were excluded from this exploratory analysis. Before engraftment, the development of fever was significantly less frequent in the pre-emptive arm (57/69, 83%) than in the empiric arm (68/71, 96%; P ¼ 0.018). The mean number of days with fever was not different for the empiric arm compared with the pre-emptive arm (when other covariates were held constant, P ¼ 0.32). Patients attending centre 1 had fewer days with fever than those at centre 2 (P ¼ 0.06). For the entire cohort, the longer the duration between transplant and onset of neutropenia, the fewer the days with fever (P ¼ 0.04). The estimated mean rate of fever was 0.41 days/days assessed in the empiric arm and 0.37 days/days assessed in the preemptive arm.
The median duration of fever did not differ between patients receiving pre-emptive or empiric antibiotics at 6 (95% CI 5,7) and 8 (95% CI 6,10) days, respectively (range 0-35 days) (P ¼ 0.51).
Addition of other antimicrobials
Of the patients undergoing allogeneic transplant, 18/39 (46%) in the pre-emptive and 22/40 (55%) in empiric arms received empiric antifungal treatment (P ¼ 0.50) ( Table 2) . Of the patients undergoing autologous HSCT, 8/36 (22%) from the pre-emptive and 20/36 (55%) patients from the empiric arms received empiric antifungal therapy (P ¼ 0.007). There was no significant difference in the median number of antimicrobial agents added after starting cefepime during transplant hospitalization in either arm, being 4 in the pre-emptive and 5 in the empiric arm (P ¼ 0.99). Antibiotic utilization (measured by expressing the daily dose of each antibiotic administered as a fraction of the accepted daily treatment dose for each day of treatment after stem cell transplantation (SCT) until discharge or death) when compared between the two groups was not different at a mean rate of antibiotic use of 3.38 standard antibiotic treatments/day in the preemptive and 4.02/day in the empiric treatment groups (P ¼ 0.64).
Bacteremias
Bacterial BSIs occurred in 16 patients (with 18 organisms) in the pre-emptive arm and in 31 patients (with 38 isolates) in the empiric arm (Po0.01) ( Table 3) . The negative binomial regression demonstrated a significant difference between the two arms that was independent of transplant type, treating hospital, age and presence of TBI and time to neutropenia. Both Gram-positive and Gram-negative isolates were reduced in the pre-emptive arm, but particularly the latter with only 2 Gram negative isolates detected in the pre-emptive arm compared to 12 in the empiric arm (Po0.01). The spectrum of Gram-positive organisms differed between the two arms, with more Staphylococcus aureus isolates in the pre-emptive arm and more Streptococcus spp in the empiric arm. Cefepime resistance was not detected in any isolate on either arm with the exception of organisms expected to demonstrate intrinsic cephalosporin resistance (Stenotrophomonas maltophilia, Enterococcus spp, MRSA). Additionally, candidemia was detected in one pre-emptive and two empiric arm patients. The estimated mean rate of infection was 0.007/day in the pre-emptive arm and 0.015/day in the empiric arm. When the results were compared between patients undergoing allogeneic and autologous transplantation, a similar reduction was seen in the proportion of patients with BSIs in the pre-emptive compared to the empiric therapy groups. In autologous transplant recipients, five patients receiving pre-emptive therapy had BSIs compared to 10 patients receiving empiric therapy. In allogeneic transplant recipients, 11 patients receiving pre-emptive therapy had BSIs compared to 21 patients receiving empiric therapy.
Patient outcome
Time to neutrophil recovery was not different between the pre-emptive and empiric arms at 13 and 12 days, respectively. The median duration of hospital stay after transplantation was 23 days for both arms (range 10-127 days). Overall mortality during admission for transplantation was 13/72 (18%) in the pre-emptive arm and 8/73 (11%) in the empiric arm. There was no difference in 30-day mortality (Table 2) . Of these deaths, three in the pre-emptive and two in the empiric arm were attributed to bacterial sepsis in the presence of positive blood cultures (two with S. aureus and one each of Clostridium tertium, Pseudomonas aeruginosa and Enterococcus sp). Median time to death after transplant was 32 days (range 5-78 days). In assessing the severity of sepsis in patients at one hospital, it was found that overall, 4/71 patients required ICU admission. Two of these were due to sepsis (one with Streptococcus pneumoniae bacteremia from the empiric arm and one with S. aureus bacteremia from the pre-emptive arm). The remaining two patients admitted to ICU had no positive blood cultures but required airway support. All other (67/71) patients had grade 1 or 2 sepsis. Of the 18 patients with grade 2 sepsis, eight were from the preemptive arm and 10 from the empiric arm.
Discussion
To our knowledge, this is the first prospective randomized study of intravenous pre-emptive compared to empiric antibiotics for fever and neutropenia in adult allogeneic and autologous HSCT recipients. Consistent with our hypothesis, patients receiving pre-emptive therapy with cefepime had a significantly longer time to onset of fever after HSCT than those receiving empiric therapy. However, this difference was only of 1 day, and there was only a minor reduction in the incidence of fever during the neutropenic phase of transplantation (relative risk 0.86). Pre-emptive antibiotics did not impact on either the number of days with fever overall or the duration of hospital admission. Although it might be expected that by starting antibiotics earlier, total antibiotic exposure would be greater, this was not the case. There was no significant difference in number of antimicrobial agents used or total antibiotic exposure between the two arms.
Consistent with our hypothesis, the number of bloodstream isolates, particularly Gram-negative organisms, was reduced in those receiving pre-emptive antibiotics. As with the delay in onset of fever, however, this did not translate into a reduction in total days of antibiotics, total doses of antibiotics, overall proportion of patients receiving empiric antifungal agents, days of hospitalization or improved survival. It should be noted however that there was a reduction in empiric antifungal use in autologous but not allogeneic HSCT recipients receiving pre-emptive antibiotic therapy. The overall proportion of autologous HSCT recipients receiving empiric antifungal therapy was high at 39% but may have reflected the underlying diseases of patients receiving autologous transplant (heavily pretreated lymphomas, myelomas or solid tumours) and the conditioning regimens used, which largely comprised mucositic regimens such as busulphan and melphalan (32%) and BEAM (24%) (data not shown). This reduction in empiric antifungal therapy is less likely to be beneficial in autologous HSCT where the risk of nephrotoxicity and its associated morbidity is not as great as in allogeneic HSCT. 18, 19 Two earlier studies of pre-emptive intravenous therapy in adults undergoing SCT undertaken in the early 1990s and late 1980s suggested a reduced incidence of BSI 1 and fever. 2 However, these trials were either not randomized 2 or included other interventions such as the use of laminar air-flow ventilation or the use of systemic non-absorbable antibiotics. 1 Recently, two studies of pre-emptive intravenous antibiotic therapy have been undertaken in adult HSCT recipients, although neither was randomized and comparative groups for both studies were drawn from different time periods. In autologous HSCT recipients, half of whom had solid tumours, oral norfloxacin begun at admission was compared with piperacillin-tazobactam begun on the day of transplant as prophylaxis.
14 This retrospective historical control study showed that 76% of the 51 patients who received piperacillin-tazobactam and 98% of the 51 patients who received norfloxacin developed fever during neutropenia. However, time to onset of fever was significantly longer in those receiving piperacillintazobactam and this was associated with a shorter total duration of antibiotic administration. In a pilot study, preemptive and empiric meropenem were compared in a cohort of 38 matched-related allogeneic transplant recipients. 13 Pre-emptive meropenem was begun on the day the neutrophil count fell to o0.5 Â 10 9 /l. Although a significant reduction in the occurrence of fever was observed with preemptive therapy (76% of patients treated pre-emptively compared with 94% treated with empiric therapy), there was no difference in the mean number of days of fever (6 days), microbiologically documented infections or use of antifungal agents.
In contrast to both these studies, 13, 14 our study did not demonstrate a reduction in the proportion of patients developing fever. The present study did not show a reduced use of antibiotics in either dose or duration and this finding was common to the study of Perez Simon et al. 13 using meropenem in allogeneic HSCT, but differed from that of Solano et al.
14 These differences in results between studies may be due to several factors.
First, differences in types of patients and type of transplantation (increased proportion of allogeneic versus autologous recipients and proportion receiving mismatched transplants) may have contributed to the lack of reduction in the number of patients with fever or antibiotic use in the present study compared to the previous studies. Our study included allogeneic HSCT recipients (52% of all patients studied and not all were matched-related transplants). As indicated by our findings of increased antibiotic use among allogeneic recipients and those receiving TBI, patients undergoing allografts have more reasons for fever, that is, more conditioning toxicity, methotrexate-related mucositis, GVHD and potentially a longer duration of neutropenia. Thus, pre-emptive antibiotics may not have had such an impact on fever and antibiotic use in our study. Further, our study was undertaken in a population dominated by patients with haematological malignancy requiring posttransplant management in hospital. Compared to patients with diseases more amenable to outpatient-based SCT, this population was less likely to benefit clinically from a reduction in the rate of fever or BSI.
Second, the differing results may reflect lesser efficacy of the drug given in our study, that is cefepime, compared with either piperacillin-tazobactam or meropenem used in the two other studies. 13, 14 A recent meta-analysis has suggested that cefepime is less effective in oncology patients with febrile neutropenia, being associated with a higher allcause mortality and bacterial superinfection rate than other beta-lactams. 20 Against this possibility, no reduction in days of antibiotics was observed in the study using meropenem as pre-emptive therapy in allogeneic transplant recipients. 13 Whether the results of the present study would have differed had piperacillin-tazobactam been chosen rather than cefepime cannot be determined, but this seems unlikely in view of the microorganisms responsible for infection in patients receiving pre-emptive cefepime.
Third, the differing results could have been due to differences in study design and sample size. Both previous studies were smaller and neither was randomized. Our study was underpowered for the detection of minor differences in duration of fever or antibiotics.
Our study suggests that pre-emptive intravenous antibiotics are unlikely to improve outcomes in patients undergoing SCT. Although time to onset of antibiotic therapy could be reduced, no overall benefit in terms of days of fever, morbidity or mortality could be associated with the delayed onset of fever. As such, these results do not support the routine use of pre-emptive antibiotic therapy in patients receiving HSCT as in-patients.
